Award
NIH Reporter #PAR-22-047
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)
Recipient
INSTITUTE FOR MOLECULAR MEDICINE
Award Amount
$1,759,263.00
Ceiling
$1,759,263.00
Awarded
August 10, 2026
Identifier
PAR-22-047
This NIH-funded project supports the development and clinical testing of the PV-1950R vaccine for Lewy Body Dementia, including manufacturing and safety studies, IND submission, and a pilot Phase 1 clinical trial.
Description
The project involves manufacturing, safety/toxicology studies, IND submission, and Phase 1 clinical trials for a vaccine targeting Lewy Body Dementia. It includes manufacturing of recombinant proteins, safety/toxicology studies in mouse and non-human primates, and clinical trials. The project is funded by the NIH/NIA and aims to develop a vaccine based on a MultiTEP platform technology, with previous development of vaccines targeting Aβ, tau, and αSyn. The project is part of a broader effort to address neurodegenerative disorders.